2019-05-01 09:27:00 Wed ET
technology antitrust patent competition bilateral trade free trade fair trade trade agreement trade surplus trade deficit multilateralism neoliberalism world trade organization regulation public utility current account compliance
Apple settles its 2-year intellectual property lawsuit with Qualcomm by agreeing to a multi-year patent license with royalty payments to the microchip maker. As part of this settlement, Apple and Qualcomm need to forego all legal actions worldwide, and the former continues to buy microchips from the latter. With a $2 increase in its latest EPS in early-2019, Qualcomm experiences a 23% share price boost well above $65, and its market capitalization surges by $14.5 billion to more than $83 billion. Qualcomm thus enjoys its best share price performance since 1999. In stark contrast, Apple faces a 3% share price decline, and also the Qualcomm microchip archrival Intel experiences a moderate share price dip.
During the fiscal year from 2018 to early-2019, Apple employs Intel microchips for the iPhone XS and XR production. Apple needs to surpass this strenuous patent settlement with Qualcomm to focus on 5G networks and revolutionary iPhone and iPad functions. With vital access to Intel and Qualcomm microchips, Apple designs 5G iPhones sooner than the late-2020 release date that numerous stock analysts anticipate. The surprise lawsuit settlement represents a *pyrrhic victory* for Apple as Qualcomm inflicts a hard toll on the smartphone bellwether.
If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.
2020-05-21 11:30:00 Thursday ET
Most blue-ocean strategists shift fundamental focus from current competitors to alternative non-customers with new market space. W. Chan Kim and Renee Ma
2022-02-02 10:33:00 Wednesday ET
Our proprietary alpha investment model outperforms most stock market indices from 2017 to 2022. As of early-January 2023, the U.S. Patent and Trademark O
2019-04-01 08:28:00 Monday ET
OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes. OraSure extracts core genetic information from microbiome s
2019-04-11 07:35:00 Thursday ET
European Central Bank designs its current monetary policy reaction function and interest rate forward guidance in response to key delays in inflation conver
2017-11-23 10:42:00 Thursday ET
As the TV host of Mad Money, Jim Cramer provides 5 key reasons against the purchase and use of cryptocurrencies such as Bitcoin. First, no one knows the ano
2019-01-10 17:31:00 Thursday ET
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be